Estimate | AL | ASAQ | |||
---|---|---|---|---|---|
Total (n = 338) | Site | Total (n = 114) | |||
Machinga (n = 112) | Nkhotakota (n = 113) | Karonga (n = 113) | |||
Participants lost to follow-up, n (%) | 35 (10.4) | 14 (12.5) | 15 (13.3) | 6 (5.3) | 16 (14) |
Treatment failure, n (%) | |||||
Early | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Late | 72 (23.8) | 22 (22.5) | 31 (31.6) | 19 (17.8) | 3 (3.1) |
Day of failure, median (range) | 21 (14, 28) | 24.5 (14, 28) | 21 (14, 28) | 21 (14, 28) | 14 (14, 21) |
Reinfection* | 70 (23.1) | 22 (22.5) | 31 (31.6) | 17 (15.9) | 2 (2) |
Recrudescence | 2 (0.66) | 0 (0) | 0 (0) | 2 (1.9) | 1 (1) |
Day 3 clearance, % (95 % CI)a | 99.7 (98.3–100) | 99.1 (94.5–100) | 100 (96.7–100) | 100 (96.7–100) | 100 (96.7–100) |
ACPR, % (95 % CI)b | |||||
Uncorrected | 76.2 (71–80.9) | 77.6 (68–83.4) | 68.4 (58.2–77.4) | 82.2 (73.7–89) | 96.9 (91.3–99.4) |
PCR-corrected | 99.3 (97.6–99.9) | 100 (96.3–100) | 100 (96.3–100) | 98.1 (93.4–100) | 99 (94.5–100) |
Kaplan–Meier survival rate on day 28, % (95 % CI)c | |||||
Uncorrected | 76.8 (72.1–81.5) | 78.2 (70.2–86.3) | 69 (59.9–78.1) | 82.5 (75.4–89.7) | 97.1 (93.9–100) |
PCR-corrected | 99.3 (98.3–100) | 100d | 100d | 98.0 (95.3–100) | 99.0 (97.2–100) |